Changchun High-Tech Industry Group Co (000661.SZ) Action Cours

Changchun High & New Technology Industries (Group), Inc. generates revenue through the research, development, production, and sale of biopharmaceuticals and proprietary Chinese medicines. Key products include polyethylene glycol recombinant human growth hormone injection, recombinant human growth hormone, recombinant human follicle stimulating hormone for injection, freeze-dried live attenuated varicella vaccines, and rabies vaccines for human use. The company also derives income from real estate development and property management services. Its primary market is domestic, serving customers within China who require pharmaceutical solutions and real estate services. The firm's biopharmaceutical segment focuses on innovative treatments such as growth hormone therapies and vaccines, targeting healthcare providers and consumers seeking advanced medical solutions. Real estate activities involve developing and managing properties, catering to residential and commercial clients in the domestic market. All operations are conducted within China, with no international expansion mentioned in the business description. Changchun High & New Technology Industries (Group), Inc. leverages its 8,841 full-time employees to support both pharmaceutical and real estate divisions. The company's product portfolio emphasizes high-demand medical treatments, including injectable growth hormones and vaccines, which are sold to domestic healthcare institutions and end-users. Real estate services complement the core business by providing additional revenue streams through property management and development.